Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2016-05-31 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Genmabs samlede antal stemmerettigheder og samlede aktiekapital
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement (Selskabsmeddelelse) from Genmab A/S regarding the total number of voting rights and share capital as of May 2016. This type of disclosure is a standard regulatory requirement for listed companies to update the market on their capital structure. Since it is a specific regulatory notification regarding share capital and voting rights, it falls under the 'Regulatory Filings' (RNS) category as it does not fit into more specific categories like 'Share Issue' (which implies a change event) or 'Major Shareholding' (which implies a third-party notification).
2016-05-31 English
Genmabs samlede antal stemmerettigheder og samlede aktiekapital
Share Issue/Capital Change Classification · 90% confidence The document is a corporate announcement under Danish disclosure rules (§ 10 in the issuer disclosure regulation) stating the nominal value and total number of shares in Genmab A/S as of the end of May 2016. This is a capital structure update (number of shares, nominal value), fitting the definition of a Share Issue/Capital Change notification.
2016-05-31 Danish
Regulatory Filings 2016
Regulatory Filings Classification · 99% confidence The document is explicitly titled "Company Announcement" and details a specific corporate event: receiving a USD 30 million milestone payment from Janssen due to the first commercial sale of DARZALEX in Europe. This is not a comprehensive financial report (like 10-K or IR), nor is it a transcript, proxy statement, or audit report. It is a specific, material corporate update concerning a partnership and revenue event. While it contains financial information, its primary function is to announce a specific business development/transaction, which aligns best with a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the milestone was related to financing terms, but RNS serves as the best general category for material, non-standardized corporate news releases that aren't earnings or dividend specific.
2016-05-30 English
Earnings Release 2016
Earnings Release Classification · 99% confidence The document is titled "Selskabsmeddelelse" (Company Announcement) in Danish and details a specific corporate event: Genmab receiving a milestone payment from Janssen due to the first commercial sale of DARZALEX in Europe. This is a specific, material event announcement, not a comprehensive periodic report (like 10-K or IR), a transcript (CT), or a general regulatory filing fallback (RNS). It is a specific announcement regarding financial/business progress related to a product milestone, which aligns best with a general corporate announcement that doesn't fit the highly specific categories like DIV, CAP, or MANG. Given the options, and since it is a formal announcement of a business development/financial event, it is closest to a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a reporting period, but it's a specific event. Since it is a formal, non-periodic announcement of a specific business event (milestone payment), and it is not a proxy statement (DEF 14A), director dealing (DIRS), or capital change (CAP/SHA), the most appropriate general category for a specific, material, non-periodic announcement that doesn't fit elsewhere is RNS (Regulatory Filings/General Announcement). However, if we consider the content is about a financial milestone payment, it is a type of corporate news release. Since RNS is the fallback for miscellaneous filings, and this is a specific company announcement, RNS is the best fit among the provided codes for a non-standard, material announcement. FY 2016
2016-05-30 Danish
Genmab når milestone på USD 30 mio. i samarbejdet med Janssen om DARZALEX® (daratumumab)
Regulatory Filings Classification · 95% confidence The document is a corporate announcement (Selskabsmeddelelse) from Genmab regarding a milestone payment of USD 30 million received from Janssen. It details the business event, provides context on the drug DARZALEX, and includes standard corporate contact and disclaimer information. It does not fit into specific financial reporting categories like 10-K or IR, nor is it a simple report publication announcement (RPA) as it contains the substantive news itself. Therefore, it is classified as a general regulatory filing/announcement.
2016-05-30 English
Genmab når milestone på USD 30 mio. i samarbejdet med Janssen om DARZALEX® (daratumumab)
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding a USD 30 million milestone payment triggered by the commercial sale of a drug. It does not fit into specific categories like financial reports, proxy statements, or board changes. As it is a general regulatory announcement regarding company operations and financial events, it falls under the RNS (Regulatory Filings) category.
2016-05-30 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.